17:53:25 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning IMMNOV 0.00 SEK
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-25 Årsstämma 2024
2024-02-21 Bokslutskommuniké 2023
2023-11-21 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-29 Ordinarie utdelning IMMNOV 0.00 SEK
2023-05-26 Årsstämma 2023
2023-05-23 Kvartalsrapport 2023-Q1
2023-03-16 Extra Bolagsstämma 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning IMMNOV 0.00 SEK
2022-04-07 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning IMMNOV 0.00 SEK
2021-05-06 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-09-23 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-08 Ordinarie utdelning IMMNOV 0.00 SEK
2020-05-07 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-04-29 Ordinarie utdelning IMMNOV 0.00 SEK
2019-04-26 Årsstämma 2019
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-04 Ordinarie utdelning IMMNOV 0.00 SEK
2018-05-03 Årsstämma 2018
2018-04-27 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-04-26 Ordinarie utdelning IMMNOV 0.00 SEK
2017-04-25 Årsstämma 2017
2017-04-20 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-12-09 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Ordinarie utdelning IMMNOV 0.00 SEK
2016-05-30 Årsstämma 2016
2016-02-24 Bokslutskommuniké 2015
2015-09-28 Extra Bolagsstämma 2015

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Immunovia är ett bioteknikbolag. Bolagets forskning och utveckling är fokuserad mot molekylärdiagnostik, där verksamheten inriktar sig på att driva utveckling och förändring av dagens arbetsmetoder för diagnostisering av komplexa cancerformer och immuna sjukdomar. Visionen är att etablera blodbaserade tester för att tidigt kunna identifiera olika sorters form av pankreascancer. Bolaget grundades 2007 och har sitt huvudkontor i Lund.
2019-09-12 15:00:00

LUND, SWEDEN- Immunovia AB (publ) ("Immunovia") today announced that Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, USA, will participate in the validation of IMMray™ PanCan-d as part of the final steps to commercialization for the blood-based test for early diagnosis of pancreatic cancer. As previously communicated, (link to PR June 3, 2019 (https://immunovia.com/investors/press-releases/?id=4915)) the final three steps towards commercialization remain the same and are as follows: 1) commercial test model; 2) verification; 3) and validation of the commercial biomarker signature. The Pancreas and Liver Institute at BIDMC will collect and share for validation 170 pancreatic adenocarcinoma (PDAC) and control blood samples from patients who have had an alarming CT scan showing suspicions of pancreatic adenocarcinoma, and as a result were referred to a GI specialist for diagnostic imaging.

Professor A. James Moser, MD, FACS, is the Director of the Pancreas and Liver Institute, Co-Director of the Pancreatic Cancer Research Program at BIDMC, and Professor of Surgery at Harvard Medical School.

The agreement between Immunovia and BIDMC adds fresh PDAC samples and controls to Immunovia's collection criteria of up to 2000 fresh samples to satisfy the needs for the remaining steps in the commercialization of IMMray™ PanCan-d.

"We are very excited to announce this collaboration with BIDMC. This partnership represents a fantastic opportunity by proximity to our Boston office and laboratory, while continuing to validate the potential our IMMray™ PanCan-d technology as well," stated Mats Grahn, Immunovia CEO.

"Early diagnosis of pancreatic cancer is critical. Patients who receive a diagnosis in the early stages have the best chances of achieving cure through current surgical procedures, chemotherapy, and radiation treatments," adds Professor Moser. "We welcome this opportunity to support efforts that work toward our shared goal: the eradication of this dreadful disease."

As previously communicated, the final steps to market for IMMray™ PanCan-d will have three readouts: 1) the commercial test model expected to be Year-End 2019; 2) the verification expected to be in Q2 2020; and 3) the final readout of the blinded validation of IMMray™ PanCan-d expected to be in Q3 2020, just prior to going to market. (link to PR June 3, 2019 (https://immunovia.com/investors/press-releases/?id=4915)).

For more information, please contact:

Julie Silber

Investor Relations Director, Immunovia

Tel.: +46-79-3486277

Email: julie.silber@immunovia.com (mats.grahn@immunovia.com)

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 (CET) on September 12, 2019.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

About Pancreatic Cancer  

Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 5-9%. It is predicted to overtake colorectal cancer to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early diagnosis can significantly improve pancreatic cancer patients' 5-year survival rates from 5-9% to up to 49%.

###